Clinical trial · Interventional
Microtransplantation for Advanced and Relapsed Solid Tumors
Efficacy and Safety of Radiotherapy or Chemotherapy Combined With Microtransplantation in the Treatment of Advanced and Relapsed Solid Tumors
NCT04937842CI-TRIAL-00052423unknownPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this study, we will apply micro transplantation to the field of solid tumors to study the efficacy and safety of radiotherapy and chemotherapy combined with micro transplantation in the treatment of advanced / relapsed solid tumors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Solid Tumors | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| microtransplantation, HLA-mismatched donor peripheral stem cell infusion | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- MST
- description
- standard chemotherapy with microtransplantation
- interventionNames
- Biological: microtransplantation, HLA-mismatched donor peripheral stem cell infusion
- type
- NO_INTERVENTION
- label
- CT
- description
- standard chemotherapy only, without microtransplantation
Primary outcomes (2)
- measure
- Treatment-Emergent Adverse Events
- timeFrame
- 1 month
- description
- Treatment related mortality
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Patients are 18-80 years old, regardless of gender or race; * Advanced / relapsed solid tumors (small cell lung cancer, ovarian cancer, cervical cancer, gastric and colorectal cancer, sarcoma, head and neck tumor, etc.) are confirmed by clinical or histopathological diagnosis; * More than two kinds of tumors are allowed; * Karnofsky score ≥ 60, ECoG physical status ≤ 2; * Sensitive to chemotherapy or radiotherapy; * There are measurable lesions; * There are suitable hematopoietic stem cell donors Exclusion Criteria: * have no suitable donor or donor refused * patient refused to accept donor cells
References
Publications (0)
Data not yet available
No reference posted for this study.